SCHEMBL722757

SCHEMBL722757

NC(=O)C[C@H](NC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MME P08473 1/20 0.62
ECE1 P42892 1/20 0.62
PPARA Q07869 3/20 0.57
PPARG P37231 1/20 0.57
ALDH1A1 P00352 1/20 0.57
RAB9A P51151 1/20 0.57
PSMB1 P20618 1/20 0.55
CASP1 P29466 3/20 0.54
ITGB3 P05106 4/20 0.54
ITGA2B P08514 4/20 0.54
CTSK P43235 2/20 0.53
TACR1 P25103 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1491365 1.00 MME (0.62) MMEECE1PPARAPPARGALDH1A1
SCHEMBL3569541 1.00 MME (0.62) MMEECE1PPARAPPARGALDH1A1
SCHEMBL11124167 0.95 MME (0.64) MMEECE1PPARAPPARGALDH1A1
Phenylacetic Acid SCHEMBL1579412 0.93 CASP1 (0.58) MMEECE1PPARAPPARGALDH1A1
SCHEMBL8955765 0.91 CTSL (0.57) MMEECE1ALDH1A1PSMB1CASP1
SCHEMBL7688519 0.91 PSMB1 (0.57) MMEECE1PSMB1CASP1CTSK
SCHEMBL11121980 0.91 MME (0.60) MMEECE1PSMB1CASP1
SCHEMBL8078067 0.90 PSMB1 (0.56) MMEECE1PSMB1CASP1CTSK
SCHEMBL20495590 0.89 MME (0.61) MMEECE1PPARAPPARGPSMB1
SCHEMBL20495591 0.89 MME (0.61) MMEECE1PPARAPPARGPSMB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4622991-A2 SYNTHESIS OF A CYCLIC PEPTIDE Janssen Pharmaceutica NV (BE) 2025-10-01 EP claimed
WO-2024110477-A2 SYNTHESIS OF A CYCLIC PEPTIDE JANSSEN PHARMACEUTICA NV (BE) 2024-05-30 WO claimed
CN-114682232-B Preparation method and application of bridged cyclodextrin/chitosan difunctional chiral monolithic column 福州大学 2023-04-21 CN claimed
CN-115029401-A Method for co-production of fulvic acid organic fertilizer by straw sugar production 蚌埠星河秸秆生物科技有限公司 2022-09-09 CN claimed
CN-114682232-A Preparation method and application of bridged cyclodextrin/chitosan bifunctional chiral monolithic column 福州大学 2022-07-01 CN claimed
EP-3988538-A1 MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) 2022-04-27 EP claimed
US-20220111055-A1 MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) 2022-04-14 US claimed
WO-2020252713-A1 MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF 浙江智达药业有限公司 2020-12-24 WO claimed
CN-112110834-A Modified hydrophobic auxiliary material and preparation method and application thereof 浙江智达药业有限公司 2020-12-22 CN claimed
US-20060287500-A1 Method for synthesis of C2-symmetric diamino diol mediated by titanium complexes DEVELOPMENT CENTER FOR BIOTECHNOLOGY 2006-12-21 US claimed
US-5757408-A PRINTING IMAGE ON SUBSTRATE COATED WITH AMINO-ACID DERIVATIVE ADDITIVE; QUICK DRYING OF INK, OPTICAL DENSITY, NONCURLING XEROX CORPORATION (US) 1998-05-26 US claimed
US-5750649-A REACTING ACID AND AMINE IN PRESENCE OF CARBODIIMIDE DEHYDRATING AGENT AND N-HYDROXY COMPOUND; PEPTIDES HOFFMANN-LA ROCHE INC. (US) 1998-05-12 US claimed
US-5683793-A Ink jet transparencies XEROX CORPORATION (US) 1997-11-04 US claimed
US-5589277-A INK JET PRINTING, AQUEOUS INKS, FAST DRYING XEROX CORPORATION (US) 1996-12-31 US claimed
US-5536816-A Process for producing amides using catalytic amounts of an N-hydroxy compound HOFFMANN-LA ROCHE INC. (US) 1996-07-16 US claimed
EP-0667246-A1 Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds XEROX CORPORATION (US) 1995-08-16 EP claimed
EP-0334236-B1 Preparation of n-protected alpha-l-aspartyl-l-phenylalanine methyl ester MITSUI TOATSU CHEMICALS (JP) 1994-08-31 EP claimed
EP-0611774-A1 Production of amides and peptides without racemization in the presence of catalytic amounts of a N-hydroxy-compound F. HOFFMANN-LA ROCHE AG (CH) 1994-08-24 EP claimed
EP-0099585-B1 PROCESS FOR PRODUCING AN ADDITION COMPOUND OF A DIPEPTIDE ESTER AND AN AMINO ACID ESTER TOYO SODA MANUFACTURING CO., LTD. (JP) 1987-11-04 EP claimed
EP-0072015-B1 METHOD FOR PURIFYING N-BENZYLOXYCARBONYL ASPARTIC ACID PPG INDUSTRIES, INC. (US) 1984-10-31 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220111055-A1 MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF CETP, SLC43A1, SLC27A1 MME 737/4885ECE1 834/4885PPARA 1752/4885
US-20060287500-A1 Method for synthesis of C2-symmetric diamino diol mediated by titanium complexes TLL2, TLL1, CTSL MME 392/4885ECE1 1464/4885PPARA 3280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.